BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer H, Yazdanpanah Y, Zuure F, Manns MP. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat 2018;25 Suppl 1:6-17. [PMID: 29508946 DOI: 10.1111/jvh.12875] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Sarrazin C, Boesecke C, Golsabahi-Broclawski S, Moog G, Negro F, Silaidos C, Patel P, Lohmann K, Spinner CD, Walcher S, Wedemeyer H, Wörns MA. Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal. Health Sci Rep 2021;4:e290. [PMID: 34136654 DOI: 10.1002/hsr2.290] [Reference Citation Analysis]
2 Tampaki M, Savvanis S, Koskinas J. Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues. Ann Gastroenterol 2018;31:670-9. [PMID: 30386116 DOI: 10.20524/aog.2018.0306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
3 Pollock KG, McDonald SA, Gunson R, McLeod A, Went A, Goldberg DJ, Hutchinson SJ, Barclay ST. Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype. J Viral Hepat 2020;27:996-1002. [PMID: 32479681 DOI: 10.1111/jvh.13337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Erice A, Varillas-Delgado D, Caballero C. Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain). J Viral Hepat 2021. [PMID: 34224188 DOI: 10.1111/jvh.13564] [Reference Citation Analysis]
5 Idilman R, Razavi H, Robbins-Scott S, Akarca US, Örmeci N, Kaymakoglu S, Aygen B, Tozun N, Güner R, Bodur H, Lazarus JV. A micro-elimination approach to addressing hepatitis C in Turkey. BMC Health Serv Res 2020;20:249. [PMID: 32209103 DOI: 10.1186/s12913-020-5019-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 . Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel. AIDS 2020;34:1699-711. [DOI: 10.1097/qad.0000000000002622] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
7 Sims S, Michaelsen K, Burkhard S, Fraefel C. In Vitro Comparison of the Internal Ribosomal Entry Site Activity from Rodent Hepacivirus and Pegivirus and Construction of Pseudoparticles. Adv Virol 2021;2021:5569844. [PMID: 34422054 DOI: 10.1155/2021/5569844] [Reference Citation Analysis]
8 Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res 2018;7:F1000 Faculty Rev-921. [PMID: 30002817 DOI: 10.12688/f1000research.14841.1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
9 Juanbeltz R, Pérez-García A, Aguinaga A, Martínez-Baz I, Casado I, Burgui C, Goñi-Esarte S, Repáraz J, Zozaya JM, San Miguel R, Ezpeleta C, Castilla J; EIPT-VHC Study Group. Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain. PLoS One 2018;13:e0208554. [PMID: 30513107 DOI: 10.1371/journal.pone.0208554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
10 Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, Johansson KA, Fadnes LT. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev Policy 2020;15:44. [PMID: 32605625 DOI: 10.1186/s13011-020-00286-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Pericàs JM, Bromberg DJ, Ocampo D, Schatz E, Wawer I, Wysocki P, Safreed-Harmon K, Lazarus JV. Hepatitis C services at harm reduction centres in the European Union: a 28-country survey. Harm Reduct J 2019;16:20. [PMID: 30898122 DOI: 10.1186/s12954-019-0290-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gardini I, Bartoli M, Conforti M, Mennini FS, Marcellusi A. Estimation of the number of HCV-positive patients in Italy. PLoS One 2019;14:e0223668. [PMID: 31671120 DOI: 10.1371/journal.pone.0223668] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
13 Cammarota S, Citarella A, Guida A, Conti V, Iannaccone T, Flacco ME, Bravi F, Naccarato C, Piscitelli A, Piscitelli R, Valente A, Calella G, Coppola N, Parruti G. The inpatient hospital burden of comorbidities in HCV-infected patients: A population-based study in two Italian regions with high HCV endemicity (The BaCH study). PLoS One 2019;14:e0219396. [PMID: 31291351 DOI: 10.1371/journal.pone.0219396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Houri I, Horowitz N, Katchman H, Weksler Y, Miller O, Deutsch L, Shibolet O. Emergency department targeted screening for hepatitis C does not improve linkage to care. World J Gastroenterol 2020; 26(32): 4878-4888 [PMID: 32921964 DOI: 10.3748/wjg.v26.i32.4878] [Reference Citation Analysis]
15 Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Økland JM, Leiva RAM, Vickerman P, Johansson KA, Fadnes LT. On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017. BMJ Open 2020;10:e036355. [PMID: 32847908 DOI: 10.1136/bmjopen-2019-036355] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Kondili LA, Aghemo A, Andreoni M, Galli M, Rossi A, Babudieri S, Nava F, Leonardi C, Mennini FS, Gardini I, Russo FP. Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. Dig Liver Dis 2021:S1590-8658(21)00142-0. [PMID: 33926816 DOI: 10.1016/j.dld.2021.03.026] [Reference Citation Analysis]
17 Kramer J, Wolffram I, Früh U, Bätz O, Berg T, Wiegand J. Laboratory reform counteracts the WHO hepatitis C elimination strategy in Germany. J Viral Hepat 2019;26:1493-5. [PMID: 31386783 DOI: 10.1111/jvh.13188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Chilaka VN, Konje JC. Viral Hepatitis in pregnancy. Eur J Obstet Gynecol Reprod Biol 2021;256:287-96. [PMID: 33259998 DOI: 10.1016/j.ejogrb.2020.11.052] [Reference Citation Analysis]
19 Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel MK, Razzack AA, Solimando AG, Thompson A, Andrews K, Enebong Nya G, Ahmad S, Ranaldo R, Cozzolongo R, Shahini E. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol Belg 2021;84:637-56. [PMID: 34965046 DOI: 10.51821/84.4.015] [Reference Citation Analysis]
20 Kim KA, Lee JS. Prevalence, Awareness, and Treatment of Hepatitis C Virus Infection in South Korea: Evidence from the Korea National Health and Nutrition Examination Survey. Gut Liver 2020;14:644-51. [PMID: 31842525 DOI: 10.5009/gnl19272] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Schmidbauer C, Chromy D, Schmidbauer V, Bauer D, Apata M, Nguyen D, Mandorfer M, Simbrunner B, Rieger A, Mayer F, Schmidt R, Holzmann H, Trauner M, Gschwantler M, Reiberger T. Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. Liver Int 2020;40:787-96. [PMID: 32017359 DOI: 10.1111/liv.14399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Pradat P, Virlogeux V, Trépo E. Epidemiology and Elimination of HCV-Related Liver Disease. Viruses 2018;10:E545. [PMID: 30301201 DOI: 10.3390/v10100545] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
23 Lancaster K, Rhodes T, Rance J. "Towards eliminating viral hepatitis": Examining the productive capacity and constitutive effects of global policy on hepatitis C elimination. Int J Drug Policy 2020;80:102419. [PMID: 30975593 DOI: 10.1016/j.drugpo.2019.02.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
24 Molinaro S, Resce G, Alberti A, Andreoni M, D′egidio PPF, Leonardi C, Nava FA, Pasqualetti P, Villa S. Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics. Drug Alcohol Rev 2019;38:644-55. [DOI: 10.1111/dar.12978] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
25 Hellard M, Schroeder SE, Pedrana A, Doyle J, Aitken C. The Elimination of Hepatitis C as a Public Health Threat. Cold Spring Harb Perspect Med 2020;10:a036939. [PMID: 31712223 DOI: 10.1101/cshperspect.a036939] [Reference Citation Analysis]
26 Hasan F, Alfadhli A, Al-Gharabally A, Alkhaldi M, Colombo M, Lazarus JV. Accelerating the elimination of hepatitis C in Kuwait: An expert opinion. World J Gastroenterol 2020; 26(30): 4415-4427 [PMID: 32874054 DOI: 10.3748/wjg.v26.i30.4415] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Hüppe D, Stoehr A, Buggisch P, Mauss S, Klinker H, Teuber G, Hidde D, Lohmann K, Bondin M, Wedemeyer H. The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). J Viral Hepat 2021. [PMID: 34339561 DOI: 10.1111/jvh.13586] [Reference Citation Analysis]
28 Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat. 2018;25 Suppl 3:6-14. [PMID: 30398294 DOI: 10.1111/jvh.13005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
29 Chilaka VN, Hassan R, Konje JC. Post-exposure prophylaxis for Blood-Borne Viral (BBV) Infections. Eur J Obstet Gynecol Reprod Biol 2020;255:83-91. [PMID: 33113403 DOI: 10.1016/j.ejogrb.2020.10.032] [Reference Citation Analysis]
30 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
31 Williams J, Miners A, Harris R, Mandal S, Simmons R, Ireland G, Hickman M, Gore C, Vickerman P. Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England. Value in Health 2019;22:1248-56. [DOI: 10.1016/j.jval.2019.06.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
32 Domovitz T, Gal-Tanamy M. Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. J Clin Med 2021;10:551. [PMID: 33540858 DOI: 10.3390/jcm10030551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Lancaster K, Rhodes T. Futuring a world without disease: visualising the elimination of hepatitis C. Critical Public Health. [DOI: 10.1080/09581596.2020.1787347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Bielen R, Kremer C, Koc ÖM, Busschots D, Hendrickx DM, Vanelderen P, Hens N, Nevens F, Robaeys G. Screening for hepatitis C at the emergency department: Should babyboomers also be screened in Belgium? Liver Int 2019;39:667-75. [PMID: 30525269 DOI: 10.1111/liv.14016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
35 Ma J, Non L, Amornsawadwattana S, Olsen MA, Garavaglia Wilson A, Presti RM. Hepatitis C care cascade in HIV patients at an urban clinic in the early direct-acting antiviral era. Int J STD AIDS 2019;30:834-42. [PMID: 31159714 DOI: 10.1177/0956462419832750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Drysdale K, Ntuli Y, Bestwick J, Gelson W, Agarwal K, Forton D, Mutimer D, Elsharkawy AM, Townley C, Mahomed F, Foster GR. English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. Aliment Pharmacol Ther 2020;52:168-81. [PMID: 32441382 DOI: 10.1111/apt.15780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Huiban L, Stanciu C, Muzica CM, Cuciureanu T, Chiriac S, Zenovia S, Burduloi VM, Petrea O, Sîngeap AM, Gîrleanu I, Sfarti C, Cojocariu C, Trifan A. Hepatitis C Virus Prevalence and Risk Factors in a Village in Northeastern Romania-A Population-Based Screening-The First Step to Viral Micro-Elimination. Healthcare (Basel) 2021;9:651. [PMID: 34072635 DOI: 10.3390/healthcare9060651] [Reference Citation Analysis]
38 Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts T, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135-184. [PMID: 30647010 DOI: 10.1016/s2468-1253(18)30270-x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 79] [Article Influence: 90.0] [Reference Citation Analysis]
39 Botterman R, Verhelst X, Buffel V, Derese A, Van Der Paelt T, De Volder G, Van Vlierberghe H, Boeckxstaens P. Hepatitis C in two general practices in Flanders, Belgium: is there a need to reconsider current screening recommendations? Acta Clin Belg 2020;:1-8. [PMID: 32436785 DOI: 10.1080/17843286.2020.1763670] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Ledesma F, Buti M, Domínguez-Hernández R, Casado MA, Esteban R. Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence. Rev Esp Quimioter 2020;33:240-8. [PMID: 32510188 DOI: 10.37201/req/030.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Erman A, Krahn MD, Hansen T, Wong J, Bielecki JM, Feld JJ, Wong WWL, Grootendorst P, Thein HH. Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. BMJ Open 2019;9:e027491. [PMID: 31719068 DOI: 10.1136/bmjopen-2018-027491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]